|
Showing 1 - 9 of
9 matches in All Departments
Reflecting current understanding of the complexities of sexual
activity among persons with chronic mental illness, the text draws
upon the collective wisdom and experience of experts from a variety
of settings. Clinicians, advocates, consumers, researchers, legal
experts, and administrators all contribute to document the concerns
about sexual behavior and the consequent health risks for this
at-risk population. The research presented here is particularly
timely in view of recent emphases on patient choice, recovery, and
advocacy, and can be used to provide guidance to clinicians, mental
health administrators, policymakers, advocates, and researchers.
Physical health and mental health are inextricably linked together.
Moreover, as the biology of mental illnesses is gradually - and
inexorably - being elucidated, the overlap between physical
illnesses and mental illnesses has become even more apparent. These
observations 'set the stage' for readers of this issue of
Psychiatric Clinics in which a variety of articles are presented
from all aspects of medicine - from emergency mental health to how
burn patients heal and cope with the physical and mental outcomes,
to coverage of issues such as prolonged stay in the intensive care
unit, comorbidities in the elderly, food allergies, depression and
other common primary care conditions, and childhood diabetes. A
primer on interviewing techniques and role play is presented along
with the role of nurses who cross both mental and physical aspects
of healthcare and the essential role of a supportive family to the
interdiscipinary team .
Schizophrenia is often associated with an inadequate response to
pharmacological and non-pharmacological treatments. How to treat
patients who have an unsatisfactory response to anti-psychotics,
including clozapine - which is unequivocally the most powerful
antipsychotic medication for this recalcitrant population - remains
a clinical conundrum. A range of adjunctive medications have been
tried with mixed results; there has also been renewed interest in
the role of neuromodulatory strategies, electroconvulsive therapy,
and cognitive and vocational approaches. Perhaps a bright spot for
the future lies in the evolution of pharmacogenetic approaches for
individualized care. In this book, leading experts from Europe,
Australia and the Americas provide a timely appraisal of treatments
for the most severely ill schizophrenia patients. This clinically
focused book is informed by the latest research on the neurobiology
and treatment of schizophrenia. It is comprehensive in scope,
covering current treatment options, various add-on approaches, and
a range of psychosocial treatments. The contributors are respected
experts who have combined their clinical experience with
cutting-edge research to provide readers with authoritative
information on fundamental aspects of clinical care for
schizophrenia.
The Year Book of Psychiatry and Applied Mental Health brings you
abstracts of the articles that reported the year's breakthrough
developments in psychiatry and mental health, carefully selected
from more than 300 journals worldwide. Expert commentaries evaluate
the clinical importance of each article and discuss its application
to your practice. There's no faster or easier way to stay informed!
Annual topics feature the latest information on biological
psychiatry, alcohol and substance-related disorders, psychiatry and
the law, psychotherapy, and clinical psychiatry.
Schizophrenia remains a poorly understood and yet a profoundly
serious condition among all the major medical illnesses. A major
shift in the past 5 years has been witnessed among psychiatrists
with the belief now that diagnosis and intervention early may have
a positive influence on the outcome of schizophrenia. This shift
has led to searching for key diagnostic clusters to enhance early
diagnosis as well as to concerted efforts to find biomarkers of
disease and disease progression. To that end, this issue of the
Psychiatric Clinics of North America is dedicated to these
contemporary issues that promote 'early intervention' in
schizophrenia. Distinguished academic clinicians and
neuroscientists provide comprehensive overviews of the present
state of knowledge on the epidemiology, early clinical
characteristics, and diagnostic changes, proposed pathogenesis,
neurobiology, and treatment requirements for this disorder. The
optimism and excitement for real progress in schizophrenia research
treatment is incorporated into this text. The current state of
knowledge is substantial, academically credible, and scientifically
based. Topics on the subject of early intervention in and diagnosis
of schizophrenia include: The Nosology of Schizophrenia: Defining
Illness Boundaries Based upon Symptoms; The Neurodevelopmental
Hypothesis of Schizophrenia: a Critical Synthesis; Predicting Risk
and the Emergence of Schizophrenia; Is Early Intervention for
Psychosis Feasible and Effective?; Can Neuroimaging Be Used to
Define Phenotypes and Course of Schizophrenia?; Reliable Biomarkers
and Predictors of Schizophrenia and Its Treatment; From Study to
Practice: Enhancing Clinical Trials Methods Toward 'Real World'
Outcomes; Relapse Prevention in Schizophrenia; Antipsychotic
Polypharmacy: Every Clinician's 'Dirty Little Secret'; Cognitive
Remediation: Retraining the Brain in Schizophrenia; Peers and
Peer-led Interventions; Homelessness; and The Emerging Role of
Technology and Social Media in Caring for People with
Schizophrenia. Each presentation in this publication includes an
Overview, Implications for Practice, with Summarizations of
Important Clinical and Learning Points.
Psychiatric comorbidities such as depression, anxiety and substance
use are extremely common amongst people with schizophrenia. They
add to poor clinical outcomes and disability, yet are often not at
the forefront of the minds of clinicians, who tend to concentrate
on assessing and treating the core symptoms of schizophrenia,
notably delusions and hallucinations. There is an imperative to
assess every patient with schizophrenia for psychiatric
comorbidities, as they might masquerade as core psychotic symptoms
and also because they warrant treatment in their own right. This
volume addresses these issues using a clinical lens informed by the
current literature. Published as part of the Oxford Psychiatry
Library series, the book serves as a concise and practical
reference for busy clinicians.
Schizophrenia is often associated with an inadequate response to
pharmacological and non-pharmacological treatments. How to treat
patients who have an unsatisfactory response to anti-psychotics,
including clozapine - which is unequivocally the most powerful
antipsychotic medication for this recalcitrant population - remains
a clinical conundrum. A range of adjunctive medications have been
tried with mixed results; there has also been renewed interest in
the role of neuromodulatory strategies, electroconvulsive therapy,
and cognitive and vocational approaches. Perhaps a bright spot for
the future lies in the evolution of pharmacogenetic approaches for
individualized care. In this book, leading experts from Europe,
Australia and the Americas provide a timely appraisal of treatments
for the most severely ill schizophrenia patients. This clinically
focused book is informed by the latest research on the neurobiology
and treatment of schizophrenia. It is comprehensive in scope,
covering current treatment options, various add-on approaches, and
a range of psychosocial treatments. The contributors are respected
experts who have combined their clinical experience with
cutting-edge research to provide readers with authoritative
information on fundamental aspects of clinical care for
schizophrenia.
This issue of the Psychiatric Clinics, edited by Dr. Peter F.
Buckley, examines advances and current management in the treatment
of Schizophrenia. The topics covered in this issue include, but are
not limited to: Duration of Untreated Psychosis (DUP) and
Longitudinal Perspectives on DUP; Neuroinflammation and
Schizophrenia; Emerging Treatments for Schizophrenia;
Treatment-Resistant Schizophrenia; Comorbidities and Schizophrenia;
Recovery from Schizophrenia; and the latest in schizophrenia
research.
Patients' failure to complete a simple prescription course presents
a tremendous public health problem and a considerable challenge for
practicing clinicians. For those with chronic mental illnesses,
non-adherence is an even greater problem than in other patient
populations and substantially lowers the possibility of improvement
or recovery. Additionally, adherence to treatment is further
undermined by impairments in insight that often accompany mental
illness. Much has been written about non-adherence across medical
specialties. Yet, the topic of non-adherence in psychiatric
patients is so common and complex that it merits review in its own
right.
Using the most up-to-date research available, this book summarizes
the current knowledge concerning non-adherence in mental illness,
presenting concise, practical information on such topics as the
reasons behind medication non-adherence, detection of
non-adherence, and the pharmacological and non-pharmacological
options available to clinicians to manage non-adherence. The
authors review the effectiveness of psycho-education, brief
counseling, compliance therapy, cognitive adaptive strategies,
reminder electronic monitoring strategies, family therapy, peer
support and recovery, and assertive community treatment (ACT), as
well as assess the legal issues around patient adherence, including
outpatient commitment and Kendra's law.
Importantly, the text also addresses the ever evolving role of
psychiatrists in managing adherence, focusing on the rapid advances
in pharmacology, in light of the new and broadening recovery
concept for mental illness. The data is presented in a
"ready-to-use" manner, utilizing algorithms, diagrams, tables, and
figures to convey helpful information to clinicians in order to
improve all aspects of psychiatric patient adherence.
|
You may like...
Catan
(16)
R1,150
R887
Discovery Miles 8 870
|